Genzyme to pay $64m to settle buyback claims
Tracking stock at heart of dispute with shareholders
Genzyme Corp. will pay $64 million to settle claims that the Cambridge biotech company schemed to buy back its Genzyme Biosurgery division from shareholders for less than it was worth. (Full article: 552 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
